Christopher Lemieux
Chercheur associé
Axe Oncologie
Dernières nouvelles
Publications
Voir tout-
article Owen C, Lemieux C, Bosch M, Davison K, Forward N, Kanasara R, Keating MM, Prica A, Stewart C, Vijenthira A, Sehn LH
Canadian Hematology Consensus Group Recommendations for the Management of Relapsed and/or Refractory Follicular Lymphoma
Curr Oncol 33 (8), 2026.
-
article Lemieux C
Practical Management of Aggressive B-Cell Lymphomas with CD20×CD3 Bispecific Antibodies
Canadian Hematology Today 2025.
-
article Lemieux C, Kuruvilla J, Shafey M, Davison K, Paulson K, Li SZL, Billen L, Nissen F, Wang HL, Kim JJ, Lee G, Hu ZH, Logan B, Feng Z, Pasquini MC, Hay K
Real-World Outcomes of Axicabtagene Ciloleucel for Treatment of Relapsed or Refractory Large B-Cell Lymphoma in Canada
Curr Oncol 33 (2), 2026.
Projets
- A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A..An ANTI-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL), du 2025-02-05 au 2031-12-25
- Axi-Cel en externe, du 2025-06-01 au 2028-06-01